A scientist who learned commerce, and a consultant who never forgot the science. He gets called when a drug has to launch right the first time.
ON THE RECORD
Akira Robinson. The smile of a man who has read your launch plan and found the gap on page nine.
Most pharmaceutical launches measure their clock in quarters. Akira Robinson now works on medicine that measures its clock in hours. Radiopharmaceuticals - drugs built around a radioactive payload aimed at a tumor - have a half-life. Wait too long between the factory and the patient and there is no product left to deliver. That is the problem he signed up for when he became interim Chief Commercial Officer at Nucleus RadioPharma in November 2025.
It is a fitting late chapter for someone whose whole career has been about closing the distance between a promising molecule and a patient who needs it. By day he is a Partner and Chief Experience Officer at Scimitar Inc., a life-sciences consultancy. By assignment he is the operator companies parachute in when the science works but the commercial machine wobbles - the interim CCO, the fractional COO, the person handed the launch nobody can afford to get wrong.
His thesis fits in four words: optimal commercialization activates patient care. Strip away the consulting gloss and it is a moral claim disguised as an operating principle. A drug that never reaches the people it was built for is, commercially and clinically, a failure - no matter how elegant the chemistry.
Robinson has roughly two decades behind that conviction. He started inside the industry at Baxter, working in hemophilia. He spent a stretch on Wall Street as an equity research analyst, grading biotech companies from the outside before deciding he would rather build them from the inside. He ran consulting engagements out of New York, London, and Los Angeles - three cities, three regulatory weather systems, one obsession with getting the launch right.
“Optimal commercialization activates patient care.”
- Akira Robinson, his four-word operating system
There is a particular kind of professional who only shows up when things are about to get serious. The molecule has cleared its trials. The investors are watching. The launch window is open and closing at the same time. That is Robinson's natural habitat.
At EVERSANA he did not join a launch practice. He built one - from the ground to more than twenty consultants focused on launch readiness, launch strategy, and the unglamorous program-management plumbing that decides whether a launch is a triumph or a cautionary slide in next year's deck. The work spanned therapeutic areas, which is another way of saying he learned the launch is never quite the same problem twice.
His range is unusually wide for a commercial leader: brand and data analytics, competitive intelligence, go-to-market architecture, portfolio and program management. The through-line is fluency. He can sit with the scientists and follow the mechanism, then turn to the board and translate it into a number. Few people do both well. The ones who do tend to end up, like Robinson, holding the interim CCO title when a company cannot wait for a permanent hire.
Readiness, sequencing, and the program-management spine that keeps a launch from quietly falling apart between functions.
Steps into Chief Commercial and Chief Operating Officer seats when a company needs senior hands immediately, not eventually.
Commercializing advanced modalities where logistics, half-life, and supply chain are part of the value proposition.
Translating clinical differentiation into market access, pricing posture, and a commercial narrative buyers believe.
Reading the signals - competitive, commercial, behavioral - that tell you whether the plan survives contact with reality.
Carrying a Stanford GSB AI-playbooks certificate into the launch room as the industry "pharmatizes" its tooling.
An impressionistic read of where his public profile puts the emphasis - drawn from his own stated expertise, not a survey.
Begins in biopharma at Baxter, working in hemophilia - close enough to the patient to never forget why the launch matters.
Covers biotechnology companies as a Wall Street equity research analyst, grading the industry from the outside.
Consulting across New York, London, and Los Angeles - data analytics, competitive intelligence, strategy.
Builds and scales EVERSANA's launch practice to 20+ consultants; takes interim CCO and COO assignments.
Joins the board of Fusion Community Empowerment, Inc.
Named Chief Commercial Officer (Ad Interim) at radiopharma CDMO Nucleus RadioPharma.
Partner & Chief Experience Officer at Scimitar; completes Stanford GSB AI-playbooks certificate; works the floor at BIO International 2026.
His handle on X tells the origin story in one word. The science came first; the commerce came later.
He talks about treating commercialization with the rigor of an early clinical trial - hypotheses, evidence, iteration.
He once rated biotech companies for investors. Then he crossed the desk to build the kind he used to grade.
Radiopharmaceuticals decay. Launch them too slowly and the product is literally gone - a logistics puzzle most marketers never face.
Partner at a consultancy and interim chief at a manufacturer at the same time. The fractional executive era, embodied.
Off the clock, he sits on the board of Fusion Community Empowerment.
“Modernizing the commercialization model through deep scientific fluency, operational resilience, and a 'Phase I' mindset.”
- What he says he is committed to